Exenatide, a GLP-1 agonist in the treatment of Type 2 diabetes

Sennik, D, Ahmed, F and Russell-Jones, D (2012) Exenatide, a GLP-1 agonist in the treatment of Type 2 diabetes Expert Review of Endocrinology and Metabolism, 7 (1). pp. 15-26.

Full text not available from this repository.

Abstract

Incretin-based therapies represent a new and innovative treatment modality in the management of Type 2 diabetes. Their therapeutic actions address many of the key metabolic defects in the pathophysiology of diabetes. Incretin hormones augment insulin secretion in a glucose-dependent manner. They have a low risk of inducing hypoglycemia, unlike many other antidiabetic medications. They also have the beneficial effect of being associated with early satiety, decreased caloric intake and weight loss. Exenatide was the first incretin-based therapy to be licensed for use and has now been developed in a once-weekly preparation. We review the evidence base for the use of exenatide and discuss the implications for the management of diabetes. © 2012 Expert Reviews Ltd.

Item Type:	Article
Divisions :	Surrey research (other units)
Authors :	Name Email ORCID Sennik, D Ahmed, F Russell-Jones, D davidrussell-jones@nhs.net
Date :	1 January 2012
DOI :	10.1586/eem.11.79
Depositing User :	Symplectic Elements
Date Deposited :	17 May 2017 09:38
Last Modified :	24 Jan 2020 17:22
URI:	http://epubs.surrey.ac.uk/id/eprint/824532

Actions (login required)

View Item

Downloads